Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

84 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genotype and Haplotype Analyses of TP53 Gene in Breast Cancer Patients: Association with Risk and Clinical Outcomes.
Vymetalkova V, Soucek P, Kunicka T, Jiraskova K, Brynychova V, Pardini B, Novosadova V, Polivkova Z, Kubackova K, Kozevnikovova R, Ambrus M, Vodickova L, Naccarati A, Vodicka P. Vymetalkova V, et al. Among authors: ambrus m. PLoS One. 2015 Jul 30;10(7):e0134463. doi: 10.1371/journal.pone.0134463. eCollection 2015. PLoS One. 2015. PMID: 26226484 Free PMC article.
Non-coding polymorphisms in nucleotide binding domain 1 in ABCC1 gene associate with transcript level and survival of patients with breast cancer.
Kunická T, Václavíková R, Hlaváč V, Vrána D, Pecha V, Rauš K, Trnková M, Kubáčková K, Ambruš M, Vodičková L, Vodička P, Souček P. Kunická T, et al. Among authors: ambrus m. PLoS One. 2014 Jul 31;9(7):e101740. doi: 10.1371/journal.pone.0101740. eCollection 2014. PLoS One. 2014. PMID: 25078270 Free PMC article.
Structural chromosomal aberrations as potential risk markers in incident cancer patients.
Vodenkova S, Polivkova Z, Musak L, Smerhovsky Z, Zoubkova H, Sytarova S, Kavcova E, Halasova E, Vodickova L, Jiraskova K, Svoboda M, Ambrus M, Hemminki K, Vodicka P. Vodenkova S, et al. Among authors: ambrus m. Mutagenesis. 2015 Jul;30(4):557-63. doi: 10.1093/mutage/gev018. Epub 2015 Mar 23. Mutagenesis. 2015. PMID: 25800034
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Davies C, et al. Lancet. 2013 Mar 9;381(9869):805-16. doi: 10.1016/S0140-6736(12)61963-1. Lancet. 2013. PMID: 23219286 Free PMC article. Clinical Trial.
84 results